Retrovir (Zidovudine, AZT)

The Latest

An Overview of Retrovir (Zidovudine, AZT)

Brand Name: Retrovir Other Name(s): AZT, ZDV, azidothymidine Drug Class: Nucleoside Reverse Transcriptase Inhibitors

By AIDSinfo

Zidovudine (Retrovir, AZT)

Table of Contents

What Is Zidovudine? Who Should Take Zidovudine? What About Drug Resistance? How Is Zidovudine Taken? What Are the Side Effects? How Does Zidovudine React With Other Drugs?

What Is Zidovudine?

Zidovudine (Retrovir) is a ...

By AIDS InfoNet

Retrovir

Brand name: Retrovir

Generic name: zidovudine, or AZT, or ZDV

Class: Nucleoside reverse transcriptase inhibitor (nucleoside, NRTI, or nuke) -- fixed dose combination

Manufacturer: ViiV Healthcare, www.viivhealthcare.com, (877) 844-8872

AWP: $535....

By Positively Aware

Retrovir (Zidovudine)

Zidovudine is supplied most commonly in film-coated tablets (300 mg, biconvex, round and white) with "GXCW3" on one side and "300" on the other. The drug also comes in capsules (100 mg), flavored syrup, and an intravenous infusion. Dosing may vary.

...

By The Center for AIDS Information & Advocacy

Chinese Government Approves Sale of a Domestic AIDS Drug

The Chinese government approved for the first time production and sale of an AIDS drug by a domestic company, potentially making cheaper HIV drugs available in China. Northeast General Pharmaceutical Factory, a state-owned drug manufacturer, said las...

By CDC National Prevention Information Network

AZT and d4T Cross-Resistance

STEP has reported data in past articles suggesting that a history of either Retrovir® (AZT) or Zerit® (d4T) might create cross-resistance to the other drug. This is due to the specific mutations that can cause resistance to both of these drugs. A stu...

By Seattle Treatment Education Project

Two Studies Shed Light on Development of d4T Resistance

Reverse transcriptase (RT) mutation patterns from ZDV-naive subjects failing d4T-containing regimens (Poster, TuPeA3014) Authored by J.E. Hernandez, A. Scarsella, J. Kaiser, L. Ross, R. Fisher, M. Johnson, N. Graham, M. St Clair Development o...

By Calvin Cohen, M.D., M.S.

Reassuring Findings About Infants Exposed to Zidovudine

Children exposed to zidovudine (ZDV, AZT) in utero and as newborns and who escaped acquiring HIV from their infected mothers show no cancers or other adverse health effects up through preschool age, according to a new study from the National Institut...

By U.S. National Institute of Allergy and Infectious Diseases

Session 84, Abstract 661: A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count 3

In this study by Fisher, et al., 137 treatment-naïve patients with fewer than 500 T-cells were randomized to receive either d4T+ddI or AZT+ddI to determine tolerability and antiretroviral effect. The poster presented in Chicago showed data on 112 pat...

By Kent Sepkowitz, M.D.

Session 50, Abstract 379: Combination Therapy with AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients with Less than 200 CD4/mm3

In this non-randomized study, Dr. Rubio and colleagues looked at the efficacy and tolerance of combination therapy with AZT + 3TC + indinavir as compared to d4T + 3TC + indinavir. They enrolled forty-four pre-treated patients (either AZT and/or ddI a...

By Kent Sepkowitz, M.D.